Cumberland Pharmaceuticals Files 8-K Report
Ticker: CPIX · Form: 8-K · Filed: Feb 4, 2025 · CIK: 1087294
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: CPRX
TL;DR
CPRX filed an 8-K for 'Other Events' on Feb 4, 2025. Details TBD.
AI Summary
On February 4, 2025, Cumberland Pharmaceuticals Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transactions or material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Cumberland Pharmaceuticals Inc. has reported a material event to the SEC, requiring public disclosure. Investors should review the full filing for details on the nature of these 'Other Events'.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific financial or operational details that would indicate a high risk.
Key Players & Entities
- CUMBERLAND PHARMACEUTICALS INC. (company) — Registrant
- February 4, 2025 (date) — Date of Report
FAQ
What specific 'Other Events' are being reported by Cumberland Pharmaceuticals Inc. in this 8-K filing?
The provided excerpt does not specify the nature of the 'Other Events'. The full filing would need to be reviewed for these details.
What is the significance of an 8-K filing for Cumberland Pharmaceuticals Inc.?
An 8-K filing is a report of unscheduled material events or corporate changes that are of importance to shareholders and the SEC.
When was this 8-K filing submitted?
The filing was submitted on February 4, 2025.
What is Cumberland Pharmaceuticals Inc.'s principal executive office address?
The address is 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203.
What is Cumberland Pharmaceuticals Inc.'s telephone number?
The telephone number is (615) 255-0068.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2025-02-04 16:37:34
Filing Documents
- cpix-20250204.htm (8-K) — 27KB
- dmdphase2study-toplineresu.htm (EX-99.1) — 26KB
- image_0.jpg (GRAPHIC) — 24KB
- 0001628280-25-003753.txt ( ) — 214KB
- cpix-20250204.xsd (EX-101.SCH) — 2KB
- cpix-20250204_lab.xml (EX-101.LAB) — 21KB
- cpix-20250204_pre.xml (EX-101.PRE) — 12KB
- cpix-20250204_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On February 5, 2025, Cumberland Pharmaceuticals Inc. ("Cumberland" or the "Company") announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it's the first successful Phase 2 study specifically targeting the cardiac complications of their condition. A copy of the release is furnished as Exhibit 99.1 . Exhibit No. Description 99.1 Press release dated February 4, 2025
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: February 4, 2025 By: /s/ John Hamm John Hamm Chief Financial Officer